RecruitingPhase 1NCT06539507

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

Studying Netherton syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: BioCryst Pharmaceuticals
Intervention: BCX17725(drug)
Enrollment: 78 enrolled
Eligibility: 12-65 years · All sexes
Timeline: 2024 – 2026

Study locations (12)

Stanford University School of Medicine, Palo Alto, California, United States
Therapeutics Clinical Research, San Diego, California, United States
Yale Center for Clinical Investigation, New Haven, Connecticut, United States
Northwestern Dermatology CTU, Chicago, Illinois, United States
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Westmead Hospital - Department of Dermatology, Sydney, New South Wales, Australia
Nucleus Network, Brisbane, Queensland, Australia
Veracity Clinical Research, Brisbane, Queensland, Australia
Hôpital Saint-Louis, Paris, France
Universitätsklinikum Heidelberg, Heidelberg, Germany
Maastricht Universitair Medisch Centrum (MUMC+), Maastricht, Netherlands
Erasmus Universitair Medisch Centrum (EMC), Rotterdam, Netherlands

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06539507 on ClinicalTrials.gov

Other trials for Netherton syndrome

Additional recruiting or active studies for the same condition.

See all trials for Netherton syndrome →

← Back to all trials